skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Pharma R&D Annual Review

Introduction Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021. We’ll assess industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Informa Pharma Intelligence’s Pharmaprojects, part of the Citeline suite of products, which has been tracking global drug development since 1980.

Pharma Competitor

This report will be followed up by our annual supplement reviewing the New Active Substance launches for the year just passed. But here, we will be entering the matrix databank, travelling through time back through 2020, and using our findings to project the course for pharma R&D as it navigates its way through one of the most turbulent periods of modern history, hopefully towards a new, gleaming, technologically advanced future.

Regular readers of this report (which has been running since 1993) will know that in recent years, I’ve threaded a different theme through each edition, to highlight points, to draw analogies, and to give a little turbo thrust into what could otherwise be a rather lengthy voyage through the subspace world of statistics, charts and tables. Themes selected so far have included astronomy, movies, the natural world, music and, last year, food and drink.

After completing the 2020 report early last February, I thought science fiction might be a fun topic for 2021’s report. Little did I know at that point that 2020 would turn out to resemble a particularly grim science fiction movie for all of us. A long time ago, in a galaxy far, far away – or last January as I prefer to call it – the world was a very different place indeed. Sure, there was this viral outbreak in China, but we’d been through these kinds of things before with SARS, MERS, swine flu, etc, right? Surely it would just fade away as before, and we and the pharma industry would continue our relentless march into the sunlit uplands of our golden futures.

{Read more}

Read also

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Citeline Study Feasibility

Pharma R&D Annual Review

Introduction Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021. We’ll assess industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Informa Pharma Intelligence’s Pharmaprojects, part of the Citeline suite of products, which has been tracking global drug development since 1980.